Literature DB >> 19059246

FGF21 N- and C-termini play different roles in receptor interaction and activation.

Junming Yie1, Randy Hecht, Jennifer Patel, Jennitte Stevens, Wei Wang, Nessa Hawkins, Shirley Steavenson, Steve Smith, Dwight Winters, Seth Fisher, Ling Cai, Ed Belouski, Ching Chen, Mark L Michaels, Yue-Sheng Li, Richard Lindberg, Minghan Wang, Murielle Véniant, Jing Xu.   

Abstract

Fibroblast growth factor-21 (FGF21) signaling requires the presence of beta-Klotho, a co-receptor with a very short cytoplasmic domain. Here we show that FGF21 binds directly to beta-Klotho through its C-terminus. Serial C-terminal truncations of FGF21 weakened or even abrogated its interaction with beta-Klotho in a Biacore assay, and led to gradual loss of potency in a luciferase reporter assay but with little effect on maximal response. In contrast, serial N-terminal truncations of FGF21 had no impact on beta-Klotho binding. Interestingly, several of them exhibited characteristics of partial agonists with minimal effects on potency. These data demonstrate that the C-terminus of FGF21 is critical for binding to beta-Klotho and the N-terminus is critical for fibroblast growth factor receptor (FGFR) activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19059246     DOI: 10.1016/j.febslet.2008.11.023

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  54 in total

1.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 2.  A review of fibroblast growth factor 21 in diabetic cardiomyopathy.

Authors:  Xiang Zhang; Luo Yang; Xiongfeng Xu; Fengjuan Tang; Peng Yi; Bo Qiu; Yarong Hao
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

3.  Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability.

Authors:  Zhifeng Huang; Yi Tan; Junlian Gu; Yang Liu; Lintao Song; Jianlou Niu; Longwei Zhao; Lakshmi Srinivasan; Qian Lin; Jingjing Deng; Yang Li; Daniel J Conklin; Thomas A Neubert; Lu Cai; Xiaokun Li; Moosa Mohammadi
Journal:  Cell Rep       Date:  2017-08-15       Impact factor: 9.423

4.  Circulating fibroblast growth factor 21 is reduced, whereas its production is increased in a fat depot-specific manner in cold-acclimated rats.

Authors:  Diane M Sepa-Kishi; Rolando B Ceddia
Journal:  Adipocyte       Date:  2018-09-20       Impact factor: 4.534

5.  Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction.

Authors:  Justin A Fletcher; Grace M Meers; M Harold Laughlin; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Appl Physiol Nutr Metab       Date:  2012-08-15       Impact factor: 2.665

6.  Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands.

Authors:  Regina Goetz; Mutsuko Ohnishi; Xunshan Ding; Hiroshi Kurosu; Lei Wang; Junko Akiyoshi; Jinghong Ma; Weiming Gai; Yisrael Sidis; Nelly Pitteloud; Makoto Kuro-O; Mohammed S Razzaque; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2012-03-26       Impact factor: 4.272

Review 7.  Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.

Authors:  Lucas D BonDurant; Matthew J Potthoff
Journal:  Annu Rev Nutr       Date:  2018-05-04       Impact factor: 11.848

8.  Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.

Authors:  Caslin A Gilroy; Stefan Roberts; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2018-03-15       Impact factor: 9.776

9.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

Review 10.  Fibroblast growth factor 21: an overview from a clinical perspective.

Authors:  Mikael Rydén
Journal:  Cell Mol Life Sci       Date:  2009-03-11       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.